-
How to manage diet in patients with dyslipidemia
Time of Update: 2022-09-03
"China Food News" (03 edition on January 7, 2022) (Editor in charge: Zhou Yan) Our reporter Wu Xueqin correspondent Lian Xuue Zhuang Pengxia Chen Kunlong, deputy chief physician of the Department of Cardiovascular Medicine, Hui'an County General Hospital, Fujian Province, introduced that dyslipidemia is also called hyperlipidemia.
-
Br J Dermatol: Dupilumab is effective in improving symptoms and signs in patients with atopic dermatitis
Time of Update: 2022-08-12
The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, controlled study leave a message here Dupilumab is an antibody against interleukin-4 receptor alpha used to treat atopic dermatitis (AD) .
-
Explore the headline Cell sub-journal: New breakthroughs in diabetes treatment
Time of Update: 2022-01-26
The discovery that FGF1-induced inhibition of lipolysis is dependent on PDE4 raises the possibility that this pathway contributes to glucose homeostasis in insulin-resistant mice .
Given the ability of PDE4D to regulate lipolysis in vivo, the researchers further explored the role of this PDE family in the metabolic activity of FGF1 .
-
Determination of acrylonitrile peroxide content for industrial use. Spectrophotometric method (3
Time of Update: 2022-01-12
2 The calibration method of potassium permanganate standard titration solution7.
3), transfer it into a 100 mL volumetric flask, dilute to the mark with water, mix thoroughly, called solution B, this solution contains about 15 mg/mL of hydrogen peroxide .
-
Fuzhou Municipal Market Supervision Administration No. 46 Food Safety Supervision Sampling Inspection Information Announcement in 2021
Time of Update: 2022-01-08
A small amount of residue will not cause acute human poisoning, but long-term consumption of food with emamectin benzoate exceeding the standard may have a certain impact on human health .
-
ARD: The short-term dose and duration-dependent risk of cardiovascular events of glucocorticoids in patients with rheumatoid arthritis initially treated with glucocorticoids
Time of Update: 2021-12-27
The study identified in the original unused glucocorticoids RA after the start of the use of corticosteroids in patients, whether in a dose-dependent manner and duration of the increase in the short term cardiovascular events (CVE) risk .
-
Titrimetric method for determination of total aldehyde content in styrene for industrial use (2
Time of Update: 2021-12-15
6 samplingTake samples according to GB/T3723 and GB/T6680 . 7 analysis stepsUse a pipette to draw 25 mL of styrene sample and add it to a conical flask with a stopper pre-set with 25 mL of methanol
-
JAMA Neurology: The Effect of Methylphenidate on Apathy in Patients with Alzheimer's Disease--ADMET-2 Randomized Clinical Trial
Time of Update: 2021-12-03
In order to more accurately clarify the clinical efficacy of methylphenidate in the treatment of Alzheimer's disease indifference, some researchers have recently conducted a larger, longer, and more effective test: methylphenidate dementia indifference test 2 (ADMET 2), a phase 3, placebo-controlled, blinded, 6-month multicenter randomized clinical trial involving 200 patients with apathy and Alzheimer's disease .
-
Mother’s age and diet affect the health of offspring
Time of Update: 2021-07-28
It aimed to measure how the health of the tsetse fly offspring is affected by the mother’s age, as well as the mother’s nutrition and mating experience.
Scientists have found that female tsetse flies that are under nutritional stress have lower fertility, have smaller offspring, and are less likely to survive starvation .
-
NEJM: Is severe asthma still difficult to treat
Time of Update: 2021-06-10
Recently, a phase 3 clinical trial published in the New England Journal of Medicine showed that tezepelumab can effectively relieve severe asthma caused by various reasons.
Compared with treatment with placebo, patients taking tezepelumab had a 56% reduction in acute asthma attacks within 52 weeks.
-
How effective is the host-oriented adjuvant treatment of tuberculosis? Which drugs can be used
Time of Update: 2021-04-18
In recent years, researchers have become more and more interested in host-directed therapy (HDT), a new and effective auxiliary treatment method for tuberculosis.
Among the four targeted treatment drugs, the researchers found that CC-11050 and everolimus showed sufficient safety and tolerability in the treatment of tuberculosis patients.
-
Lancet oncol: Phase 3 | Pembrolizumab as a second and third-line therapy for metastatic triple-negative breast cancer
Time of Update: 2021-03-20
In summary, the use of pembrolizumab in previously treated metastatic triple-negative breast cancer failed to significantly prolong the overall survival of patients compared with chemotherapy .
1016/S1470-2045(20)30754-3" target="_blank" rel="noopener">Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial .
-
Lancet oncol: The phase III clinical trial of the domestic drug Sofantini for advanced pancreatic neuroendocrine tumors was terminated early because of the good efficacy
Time of Update: 2020-10-04
The patients were randomly assigned to the Sovantinib group (300 mg, oral, 1/day) or placebo group at 2:1 until the disease progressed, insulable toxicity, withdrawal from the study, adverse complications, use of other anti-tumor drugs, pregnancy, loss of visitation, or the evaluation of the suspension of the patient.
-
Blood: The efficacy of BTKi, a self-developed drug, in the long-term treatment of Fahrenheit globulinemia
Time of Update: 2020-08-22
ORR and VGPR/CR rates were 95.9 per cent and 45.2 per cent, respectively, and the VGPR/CR rates increased over time: 20.5 per cent at 6 months, 32.9 per cent at 12 months and 43.8 per cent at 24 months.
-
Arthritis Rheumatol: Phase 2 Randomized Trial of Lorevante's Treatment of Knee Osteoarthritis
Time of Update: 2020-05-29
The study was designed to assess the safety and efficacy of the new Wnt pathway regulator, Lorevent (SM04690), for the treatment of pain and inhibitive structural progression in moderate to severe
